About Xeltis
Xeltis is a company based in Zurich (Switzerland) founded in 2006.. Xeltis has raised $176.03 million across 13 funding rounds from investors including EQT, European Investment Bank and Kurma Partners. Xeltis offers products and services including Artificial Vessels, Heart Valves, and RestoreX Platform. Xeltis operates in a competitive market with competitors including PECA Labs, Occlutech, Endonovo Therapeutics, Coherex and CoAptus Medical, among others.
- Headquarter Zurich, Switzerland
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$176.03 M (USD)
in 13 rounds
-
Latest Funding Round
$11.61 M (USD), Series D
Dec 02, 2025
-
Investors
EQT
& 11 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Xeltis
Xeltis offers a comprehensive portfolio of products and services, including Artificial Vessels, Heart Valves, and RestoreX Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Devices that regenerate into patients' tissue to treat vascular conditions.
Implants for pulmonary replacement to reduce surgical complications.
ETR-based system for developing self-healing vascular solutions.
Unlock access to complete
Unlock access to complete
Funding Insights of Xeltis
Xeltis has successfully raised a total of $176.03M across 13 strategic funding rounds. The most recent funding activity was a Series D round of $11.61 million completed in December 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 13
- Last Round Series D — $11.6M
-
First Round
First Round
(02 Dec 2014)
- Investors Count 12
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2025 | Amount | Debt – Conventional - Xeltis | Valuation |
investors |
|
| Dec, 2025 | Amount | Series D - Xeltis | Valuation |
investors |
|
| Aug, 2023 | Amount | Series D - Xeltis | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Xeltis
Xeltis has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include EQT, European Investment Bank and Kurma Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Founded Year | Domain | Location | |
|
Venture capital firm investing in healthcare sectors
|
Founded Year | Domain | Location | |
|
EQT is recognized as a global investment organization focused on value creation.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Xeltis
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Xeltis
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Xeltis Comparisons
Competitors of Xeltis
Xeltis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PECA Labs, Occlutech, Endonovo Therapeutics, Coherex and CoAptus Medical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Pediatric cardiac surgical devices are developed for congenital heart defects.
|
|
| domain | founded_year | HQ Location |
Provider of minimally invasive cardiac devices for congenital heart defects, stroke prevention and heart failure
|
|
| domain | founded_year | HQ Location |
Bioelectronic devices are developed for regenerative medicine therapies.
|
|
| domain | founded_year | HQ Location |
Structural heart disease conditions are addressed with implant devices.
|
|
| domain | founded_year | HQ Location |
Develops non-implant therapeutics for treating patent foramen ovale, a structural heart defect.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Xeltis
Frequently Asked Questions about Xeltis
When was Xeltis founded?
Xeltis was founded in 2006 and raised its 1st funding round 8 years after it was founded.
Where is Xeltis located?
Xeltis is headquartered in Zurich, Switzerland.
Is Xeltis a funded company?
Xeltis is a funded company, having raised a total of $176.03M across 13 funding rounds to date. The company's 1st funding round was a Series D of $13.68M, raised on Dec 02, 2014.
What does Xeltis do?
Xeltis was founded in 2006 in Zurich, Switzerland, where bioabsorbable synthetic heart valves and vascular grafts are developed for cardiovascular applications. These implants are designed to mimic natural valves and vessels, enabling the body to heal by forming native tissue as the synthetic matrix is gradually absorbed. Operations center on pediatric solutions, including a flagship pulmonary valve replacement for congenital heart malformations. The sector involves regenerative medical devices.
Who are the top competitors of Xeltis?
Xeltis's top competitors include PECA Labs, Endonovo Therapeutics and Occlutech.
What products or services does Xeltis offer?
Xeltis offers Artificial Vessels, Heart Valves, and RestoreX Platform.
Who are Xeltis's investors?
Xeltis has 12 investors. Key investors include EQT, European Investment Bank, Kurma Partners, European Union, and Life Sciences Partners.